As a protracted battle between Vertex (VRTX) Pharmaceuticals (VRTX) and the U.K. drags on over pricing for cystic fibrosis drugs, a coalition of families, patient advocates, academics, and physicians from more than a dozen countries are urging the company to lower its prices and widen access to “desperate patients.”

In an open letter to Vertex chief executive Jeffrey Leiden, the ad hoc group praised the company for “inspirational science and dedication,” but also chastised the drug maker for not doing more to ensure its medicines reach every potential patient.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The CF Foundation funds a lot of research, including a lot of the research that led to the Vertex medications approved and in development if I’m not mistaken. Do they have a corresponding arm to help patients pay for the treatments they helped to bring to market?

  • Considering the tremendous amount of money raised by the CF foundation for research, Vertexes price gouging is unconscionable.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy